The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer

Ovarian cancer is the 5th leading cause of cancer death among women in the United States. The mevalonate pathway is thought to be a potential oncogenic pathway in the pathogenesis of ovarian cancer. Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibitor, is a widely used drug for...

Descripción completa

Detalles Bibliográficos
Autores principales: Stine, Jessica E., Guo, Hui, Sheng, Xiugui, Han, Xiaoyun, Schointuch, Monica N., Gilliam, Timothy P., Gehrig, Paola A., Zhou, Chunxiao, Bae-Jump, Victoria L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808044/
https://www.ncbi.nlm.nih.gov/pubmed/26503475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808044/
https://www.ncbi.nlm.nih.gov/pubmed/26503475

Ejemplares similares